# Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

> **NCT05853367** · PHASE1 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 178 (estimated)

## Conditions studied

- Metastatic Solid Tumors
- Advanced Solid Tumors

## Interventions

- **DRUG:** MK-0472
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** MK-1084

## Key facts

- **NCT ID:** NCT05853367
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2028-02-12
- **Final completion:** 2028-02-12
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05853367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05853367, "Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05853367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*